Document:

EX-4.14

 Exhibit 4.14 

QWEST CORPORATION 
 6.875% Notes
due 2054 
  
  

Thirteenth Supplemental Indenture 

Dated as of September 29, 2014 
  

 
 U.S. BANK
NATIONAL ASSOCIATION, 
 as Trustee 

 THIRTEENTH SUPPLEMENTAL INDENTURE dated as of September 29, 2014 (this “Supplemental
Indenture”) by and between QWEST CORPORATION, a Colorado corporation (formerly named U S WEST Communications, Inc.) (the “Company”), and U.S. BANK NATIONAL ASSOCIATION, as trustee under the Indenture (as defined below) with respect to
the Notes (as defined below) (the “Trustee”), as amended and supplemented by the First Supplemental Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture, the Fourth Supplemental Indenture, the Fifth Supplemental
Indenture, the Sixth Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth Supplemental Indenture, the Eleventh Supplemental Indenture and the Twelfth Supplemental
Indenture, each as defined below. The Trustee, and each other trustee appointed as such with respect to the Securities (as defined below) of any series issued under the Indenture, shall be the “Trustee” (as defined in the Indenture, as
supplemented hereby) for all purposes under the Indenture with respect to the applicable series of Securities but, for the avoidance of doubt, not with respect to any series of Securities for which such Trustee has not been appointed trustee under
the terms of the Indenture or any supplement thereto. 
 RECITALS 

WHEREAS, the Company and Bank of New York Trust Company, National Association (as successor in interest to Bank One Trust Company, N.A. and
J.P. Morgan Trust Company, National Association), are parties to that certain Indenture dated as of October 15, 1999 (the “Base Indenture”, and as amended and supplemented by the First Supplemental Indenture, the Second Supplemental
Indenture, the Third Supplemental Indenture, the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth Supplemental Indenture, the Ninth Supplemental
Indenture, the Tenth Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth Supplemental Indenture and this Supplemental Indenture, the “Indenture”) providing for the issuance from time to time of senior debt securities
(“Securities”) to be issued in one or more series. 
 WHEREAS, the Company and the Trustee are parties to the First Supplemental
Indenture (the “First Supplemental Indenture”) dated as of August 19, 2004, providing for the amendment and supplement of the terms of the Base Indenture and the issuance by the Company of a series of Securities designated as its
7.875% Notes due 2011, in an aggregate principal amount of $575,000,000, none of which are currently outstanding. 
 WHEREAS, the Company
and the Trustee are parties to the Second Supplemental Indenture (the “Second Supplemental Indenture”) dated as of November 23, 2004, providing for the issuance by the Company of additional notes of a series of Securities designated
as its 7.875% Notes due 2011, in an aggregate principal amount of $250,000,000, none of which are currently outstanding. 
 WHEREAS, the
Company and the Trustee are parties to the Third Supplemental Indenture (the “Third Supplemental Indenture”) dated as of June 17, 2005, providing for the issuance by the Company of a series of Securities designated as its 7.625% Notes
due 2015, in an aggregate principal amount of $400,000,000, $91,885,000 of which are currently outstanding, and a series of Securities designated as its Floating Rate Notes due 2013, in an aggregate principal amount of $750,000,000, none of which
are currently outstanding. 

 WHEREAS, the Company and the Trustee are parties to the Fourth Supplemental Indenture (the
“Fourth Supplemental Indenture”) dated as of August 8, 2006, providing for the issuance by the Company of a series of Securities designated as its 7.5% Notes due 2014, in an aggregate principal amount of $600,000,000, all of which are
currently outstanding. 
 WHEREAS, the Company and the Trustee are parties to the Fifth Supplemental Indenture (the “Fifth Supplemental
Indenture”) dated as of May 16, 2007, providing for the issuance by the Company of a series of Securities designated as its 6.5% Notes due 2017, in an aggregate principal amount of $500,000,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Sixth Supplemental Indenture (the “Sixth Supplemental Indenture”) dated as
of April 13, 2009, providing for the issuance by the Company of a series of Securities designated as its 8-3/8% Notes due 2016, in an aggregate principal amount of $810,500,000, $235,007,000 of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Seventh Supplemental Indenture (the “Seventh Supplemental Indenture”) dated
as of June 8, 2011, providing for the issuance by the Company of a series of Securities designated as its 7.375% Notes due 2051, in an aggregate principal amount of $661,250,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Eighth Supplemental Indenture (the “Eighth Supplemental Indenture”) dated as
of September 21, 2011, providing for the issuance by the Company of a series of Securities designated as its 7.50% Notes due 2051, in an aggregate principal amount of $575,000,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Ninth Supplemental Indenture (the “Ninth Supplemental Indenture”) dated as
of October 4, 2011, providing for the issuance by the Company of a series of Securities designated as its 6.75% Notes due 2021, in an aggregate principal amount of $950,000,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Tenth Supplemental Indenture (the “Tenth Supplemental Indenture”) dated as
of April 2, 2012, providing for the issuance by the Company of a series of Securities designated as its 7.00% Notes due 2052, in an aggregate principal amount of $525,000,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Eleventh Supplemental Indenture (the “Eleventh Supplemental Indenture”)
dated as of June 25, 2012, providing for the issuance by the Company of a series of Securities designated as its 7.00% Notes due 2052, in an aggregate principal amount of $400,000,000, all of which are currently outstanding. 

WHEREAS, the Company and the Trustee are parties to the Twelfth Supplemental Indenture (the “Twelfth Supplemental Indenture”) dated
as of May 23, 2013, providing for the issuance by the Company of a series of Securities designated as its 6.125% Notes due 2053, in an aggregate principal amount of $775,000,000, all of which are currently outstanding. 

  
 2 

 WHEREAS, the Company desires and has requested the Trustee to execute and deliver this
Supplemental Indenture in order to establish and provide for the issuance by the Company of a series of Securities designated as its 6.875% Notes due 2054 (the “Notes”). 

WHEREAS, Section 9.01(8) of the Base Indenture provides that a supplemental indenture may be entered into by the Company and the Trustee
without the consent of any Holders to establish the form and terms and conditions of Securities of any Series as permitted by Section 2.02 of the Base Indenture. 

WHEREAS, the conditions set forth in the Indenture for the execution and delivery of this Supplemental Indenture have been complied with. 

WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement of the Company and the Trustee, in accordance with its
terms, and a valid supplement to the Indenture have been done. 
 NOW, THEREFORE, in consideration of the premises and the purchase and
acceptance of the Notes by the holders thereof (the “Holders”), the Company covenants and agrees with the Trustee, for the equal and ratable benefit of the Holders of the Notes, that the Indenture is hereby supplemented, to the extent
expressed herein, as follows: 
 ARTICLE 1 

THE NOTES 
 Section 1.01 Designation of
Notes. The changes, modifications and supplements to the Indenture effected by this Supplemental Indenture shall be applicable only with respect to, and govern the terms of, the Notes, which shall not be limited in aggregate principal amount,
and shall not apply to any other Securities that have been or may be issued under the Indenture unless a supplemental indenture with respect to such other Securities specifically incorporates such changes, modifications and supplements. Pursuant to
this Supplemental Indenture, there is hereby created and designated a series of Securities under the Indenture entitled “6.875% Notes due 2054” in an aggregate principal amount initially limited on the date hereof to $500,000,000 (plus
such additional principal amount of Notes, not exceeding $75,000,000, that may be subsequently issued pursuant to an exercise (in whole or in part) of the over-allotment option by the underwriters of the Notes). Subject to the terms in the
Indenture, as supplemented by this Supplemental Indenture, the Company may, at its option, without the consent of the Holders of the Notes, issue additional notes from time to time that will constitute a single series of Securities under the
Indenture together with the previously outstanding Notes. 
 Section 1.02 Other Terms of the Notes. Without limiting the foregoing provisions of this
Article 1, the terms of the Notes shall be as set forth in the form set forth in Exhibit A hereto and as provided in the Indenture. The Notes shall be issuable in denominations of $25 and integral multiples of $25 in excess thereof. 

  
 3 

 Section 1.03 Agents. 

(a) The Notes shall be payable and may be presented for payment, purchase, registration of transfer and exchange, without service charge, at
the office of the Company maintained for such purpose in New York, New York, which shall initially be the office or agency of the Trustee. 

(b) The Trustee shall also serve as security registrar for the purpose of registering the Notes and transfers or exchanges of the Notes. 

(c) The Company may from time to time designate one or more additional offices or agencies where Notes may be presented or surrendered for
payment or may be surrendered for registration of transfer or exchange in accordance with the Base Indenture. 
 Section 1.04 Definitions. 

(a) Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Indenture. To the extent
terms defined herein differ from the Indenture, the terms defined herein will govern. 
 (b) For all purposes of the Indenture, except as
otherwise expressly provided or unless the context otherwise requires, the terms defined in this Supplemental Indenture have the meanings assigned to them in this Supplemental Indenture, and include the plural, as well as the singular. 

ARTICLE 2 
 ADDITIONAL
TERMS 
 Section 2.01 Form and Dating. 

(a) The Notes issued shall be represented by one or more global notes substantially in the form set forth in Exhibit A hereto, deposited
with the Trustee, as custodian for The Depository Trust Company, New York, New York, or a successor depository thereto registered under the Securities Exchange Act of 1934, as amended, or other applicable statute or regulation (the
“Depository”), duly executed by the Company and authenticated by the Trustee as hereinafter provided and shall bear any legends required by applicable law (the “Global Notes”). 

(b) The aggregate principal amount of each of the Global Notes may from time to time be increased or decreased by adjustments made by the
Trustee on Schedule I to the Global Notes and on the records of the Trustee, as custodian for the Depository. 
 Section 2.02 Book-Entry Provisions
for Global Notes. 
 (a) The Global Notes initially shall (i) be registered in the name of the Depository or the
nominee of such Depository, (ii) be delivered to the Trustee as custodian for such Depository and (iii) bear the legends required by the Depository as set forth in Exhibit A. 

  
 4 

 (b) Members of, or participants in, the Depository (“Participants”) shall have no
rights under this Indenture with respect to any Global Note held on their behalf by the Depository, or the Trustee as its custodian, or under any such Global Note, and the Depository may be treated by the Company, the Trustee and any agent of the
Company or the Trustee as the absolute owner of the Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee from giving effect to any
written certification, proxy or other authorization furnished by the Depository or impair, as between the Depository and Participants, the operation of customary practices governing the exercise of the rights of a Holder of any Note. 

(c) The Holder of any Global Note may grant proxies and otherwise authorize any Person, including Participants and Persons that may hold
interests through Participants, to take any action which a Holder of any Note is entitled to take under this Indenture or the Notes. 
 (d)
Notwithstanding any other provisions of the Indenture, a Global Note may only be transferred in whole, and not in part, and may not be transferred as a whole except by the Depository to a nominee of the Depository or by a nominee of the Depository
to the Depository or another nominee of the Depository or by the Depository or any such nominee to a successor Depository or a nominee of such successor Depository. Certificated Notes shall be transferred to all beneficial owners in exchange for
their beneficial interests in Global Notes if (i) the Depository notifies the Company that it is unwilling or unable to act as Depository for any Global Note and a successor Depository is not appointed by the Company within 90 days,
(ii) the Depository ceases to be a clearing agency registered or in good standing under the Securities Exchange Act of 1934, as amended, or other applicable statute or regulation, and a successor Depository is not appointed by the Company
within 90 days or (iii) if an Event of Default shall have occurred and be continuing, but only if, in the case of item (i) or (ii) above, the Company provides written transfer directions to the Trustee or, in the case of item
(iii) above, the holders of a majority of the aggregate principal amount of the Notes provide written transfer directions to the Trustee. In addition, certificated Notes shall be transferred to all beneficial owners in exchange for their
beneficial interests in Global Notes if the Company, in its sole discretion, determines not to require that all of the Notes be represented by a Global Note. In connection with the transfer of a Global Note in its entirety pursuant to this
Section 2.02(d), such Global Note shall be deemed to be surrendered to the Trustee for cancellation and (i) the Company shall execute and (ii) the Trustee shall, upon written instructions from the Company, authenticate and deliver to
each beneficial owner identified by the Depository, in exchange for its beneficial interest in such Global Note, an equal aggregate principal amount of certificated Notes of authorized denominations. 

(e) The Trustee shall have no responsibility for the actions or omissions of the Depository or the accuracy of the books and records of the
Depository. 

  
 5 

 ARTICLE 3 

MISCELLANEOUS 
 Section 3.01 Amendment
and Supplement. This Supplemental Indenture and the Notes may be amended or supplemented as provided for in the Indenture. 
 Section 3.02
Indenture. As supplemented hereby, the Indenture is in all respects ratified and confirmed, and the Base Indenture, as heretofore amended, and this Supplemental Indenture shall be read and construed as one and the same instrument. In the
event of any conflict between this Supplemental Indenture and the Indenture, the provisions of this Supplemental Indenture shall prevail. 
 Section 3.03
Governing Law. The laws of the State of New York shall govern this Supplemental Indenture and the Notes created hereby. 
 Section 3.04 No Adverse
Interpretation of Other Agreements. This Supplemental Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary. Any such indenture, loan or debt agreement may not be used to interpret this
Supplemental Indenture. 
 Section 3.05 Successors and Assigns. 

All covenants and agreements of the Company in this Supplemental Indenture and the Notes shall bind its successors and its assigns under the
Base Indenture. All agreements of the Trustee in this Supplemental Indenture shall bind its successors and its assigns under the Base Indenture. 
 Section
3.06 Counterparts. This Supplemental Indenture may be executed in counterparts, each of which shall be an original, but such counterparts shall together constitute but one instrument. 

Section 3.07 Severability. In case any one or more of the provisions contained in this Supplemental Indenture or in the Notes shall for any reason be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Supplemental Indenture or of the Notes. 

[Signature Page Follows] 

  
 6 

 SIGNATURES 

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed, all as of the date first above written. 

 

			
	QWEST CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	  

	Name:	 	
	Title:	 	

 Exhibit A 

THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A
NOMINEE OF A DEPOSITORY OR A SUCCESSOR DEPOSITORY. THIS NOTE IS NOT EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF
THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A NOMINEE OF THE DEPOSITORY TO THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY OR BY THE DEPOSITORY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITORY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITORY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

  
 A-1 

			
	No.         	 	PRINCIPAL AMOUNT
	CUSIP No. 74913G 105	 	$            

 Qwest Corporation 6.875% Note due 2054 

QWEST CORPORATION, a corporation duly organized and existing under the laws of the State of Colorado (such corporation, and its successors and
assigns under the Indenture hereinafter referred to, being herein called the “Company”), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of
                MILLION DOLLARS ($        ) (or such other amount as shall be listed on Schedule I attached hereto) on
October 1, 2054 (the “Maturity Date”), unless previously redeemed on any redemption date, by wire transfer of immediately available funds of such coin or currency of the United States of America as at the time of payment shall be
legal tender for the payment of public and private debts and to pay interest thereon quarterly on January 1, April 1, July 1 and October 1 of each year, commencing January 1, 2015 (each, an “Interest Payment
Date”), and on the Maturity Date at the rate per annum specified in the title of this Note, from September 29, 2014 (or from the most recent Interest Payment Date to which interest has been paid or duly provided for) until payment of such
principal sum has been made or duly provided for. Notwithstanding the foregoing, if the Company shall default in the payment of interest due on any Interest Payment Date, then this Note shall bear interest from the most recent Interest Payment Date
to which interest has been paid or duly provided for or, if no interest has been paid on this Note or duly provided for, from September 29, 2014. The interest so payable on any Interest Payment Date, as long as the Notes (as defined below) are
represented by a global security, subject to certain exceptions provided in the Indenture referred to herein, will be paid to the person in whose name this Note shall be registered at the close of business on the Business Day (as defined below)
prior to such Interest Payment Date. If any Interest Payment Date or the Maturity Date is a Legal Holiday in New York, New York, the required payment shall be made on the next succeeding Business Day as if it was made on the date such payment was
due and no interest will accrue on the amount so payable for the period from and after such Interest Payment Date or Maturity Date, as the case may be, to such next succeeding Business Day. Interest will be computed on the basis of a 360-day year
consisting of twelve 30-day months. The amount of interest payable for any period shorter than a full quarterly interest period will be computed on the basis of the number of days elapsed in a 90-day quarter of three 30-day months. “Business
Day” means any day other than a Legal Holiday. 
 This Note is one of the duly authorized series of Securities of the Company,
designated as the Company’s “6.875% Notes due 2054” (the “Notes”), initially limited on the date hereof to the aggregate principal amount of $500,000,000 (or $575,000,000 if the over-allotment option of the underwriters of
the Notes is subsequently exercised in full), all issued or to be issued under and pursuant to an Indenture dated as of October 15, 1999 between the Company and Bank of New York Trust Company National Association, as trustee (as successor in
interest to Bank One Trust Company, N.A. and J.P. Morgan Trust Company, National Association), as amended and supplemented by the First Supplemental Indenture dated as of August 19, 2004 between the Company and U.S. Bank National Association,
as trustee (the “Trustee”), the Second Supplemental Indenture dated as of November 23, 2004 between the Company and the Trustee, 

  
 A-2 

 
the Third Supplemental Indenture dated as of June 17, 2005 between the Company and the Trustee, the Fourth Supplemental Indenture dated as of August 8, 2006 between the Company and the
Trustee, the Fifth Supplemental Indenture dated as of May 16, 2007 between the Company and the Trustee, the Sixth Supplemental Indenture dated as of April 13, 2009 between the Company and the Trustee, the Seventh Supplemental Indenture
dated as of June 8, 2011 between the Company and the Trustee, the Eighth Supplemental Indenture dated as of September 21, 2011 between the Company and the Trustee, the Ninth Supplemental Indenture dated as of October 4, 2011 between
the Company and the Trustee, the Tenth Supplemental Indenture dated as of April 2, 2012 between the Company and the Trustee, the Eleventh Supplemental Indenture dated as of June 25, 2012 between the Company and the Trustee, the Twelfth
Supplemental Indenture dated as of May 23, 2013 between the Company and the Trustee and the Thirteenth Supplemental Indenture dated as of September 29, 2014 between the Company and the Trustee, as such may be further amended, modified or
supplemented from time to time (as so amended, modified or supplemented, the “Indenture”), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitation of rights,
obligations, duties and immunities thereunder of the Trustee, the Company and the Holders (the words “Holders” or “Holder” meaning the registered holders or registered holder of the Notes). 

The Notes shall be redeemable at the option of the Company, in whole or in part, at any time on and after October 1, 2019, at a
redemption price equal to 100% of the principal amount redeemed plus accrued and unpaid interest to, but not including, the redemption date. 

If money sufficient to pay the redemption price of and accrued interest on all of the Notes (or portions thereof) to be redeemed on the
redemption date is deposited with the Trustee or paying agent on or before the redemption date and certain other conditions specified in the Indenture are satisfied, then on and after such redemption date, interest will cease to accrue on such Notes
(or such portion thereof) called for redemption. 
 Notice of any redemption will be mailed not less than 15 nor more than 60 calendar days
before the redemption date to the Holder hereof at its registered address. Unless the Company defaults in payment of the redemption price, on and after the redemption date interest will cease to accrue on the principal amount of the Notes called for
redemption. Neither the Company nor the Trustee shall be required to register the transfer of or exchange the Notes to be redeemed by the Company under the terms hereof. 

In case an Event of Default shall occur and be continuing, the principal hereof may be declared, and upon such declaration shall become, due
and payable in the manner, with the effect and subject to the conditions provided in the Indenture. 
 Subject to certain specified
exceptions, the Indenture contains provisions permitting (i) the Company and the Trustee, with the written consent of the Holders of a majority in principal amount of the outstanding Securities of each series affected by a supplemental
indenture (with each series voting as a class), to enter into a supplemental indenture to add any provisions to or to change or eliminate any provisions of the Indenture or of any supplemental indenture or to modify, in certain specified instances
without the consent of Holders, the rights of the Holders of each such series, and (ii) the Holders of a majority in principal amount of the outstanding Securities of each series affected by such waiver (with each series voting as a class), by
notice to the Trustee, to waive compliance by the Company with any provision of the Indenture, any supplemental indenture or the Securities of any such series. 

  
 A-3 

 No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Note at the place, at the respective times, at the rate, and in the coin or currency herein
prescribed. 
 No director, officer, employee or stockholder, as such, of the Company shall have any liability for any obligations of the
Company under this Note or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. Each Holder, by accepting this Note, waives and releases all such liability. The waiver and release are part of the
consideration for the issue of this Note. 
 The laws of the State of New York shall govern the Indenture and this Note. 

Ownership of this Note shall be proved by the register for the Notes kept by the Registrar. The Company, the Trustee and any agent of the
Company may treat the person in whose name a Note is registered as the absolute owner thereof for all purposes. 
 The indebtedness
evidenced by this Note is senior and unsecured and will rank in right of payment on parity with all other unsecured and unsubordinated obligations of the Company. 

Terms used herein without definition that are defined in the Indenture shall have the meanings assigned to them in the Indenture. 

Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused the CUSIP
number to be printed on the Notes and the Trustee may use such CUSIP number in notices of redemption as a convenience to Holders. No representation is made as to the accuracy of such number either as printed on the Notes or as contained in any
notice of redemption. 
 Unless the Certificate of Authentication hereon has been executed by the Trustee under the Indenture referred to
herein by the manual signature of one of its authorized officers, or on behalf of the Trustee by the manual signature of an authorized officer of the Trustee’s authenticating agent, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose. 
 [Signature Page Follows] 

  
 A-4 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed, manually or by
facsimile, and its corporate seal or a facsimile of its corporate seal to be imprinted hereon. 
 Date:
[                    ] 
  

							
		 		 	QWEST CORPORATION
				
	(SEAL)	 		 		 	
				
		 		 	By:	 	  

		 		 	Name:	 	
		 		 	Title:	 	
				
		 		 	By:	 	  

		 		 	Name:	 	
		 		 	Title:	 	

  
 A-5 

 CERTIFICATE OF AUTHENTICATION 

This is one of the Notes of the series designated herein, issued under the Indenture described herein. 

 

			
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	  

		 	Authorized Signatory

  
 A-6 

 SCHEDULE I 

CHANGES TO PRINCIPAL AMOUNT OF SECURITIES EVIDENCED BY GLOBAL NOTE 

The initial principal amount of Securities evidenced by this Global Note is $        . 

 

							
	 Date
	 	 Principal Amount of

Securities by which

this Global Note is to

be Reduced or

Increased, and Reason
 for
Reduction or
 Increase
	 	 Remaining Principal

Amount of Securities

Represented by this
 Global
Note
	 	 Notation Made by

		 		 		 	
		 		 		 	
		 		 		 	

  
 A-7EX-10.01

 Exhibit 10.01 

EXECUTIVE EMPLOYMENT AGREEMENT 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), dated as of September 24, 2014, (the “Effective Date”) is
made and entered by and between Symantec Corporation, a Delaware corporation (the “Company”), and Michael A. Brown (the “Executive”). 

WHEREAS, the Executive has accepted permanent employment with the Company as of September 24, 2014 (“Hire Date”) as the
Company’s President and Chief Executive Officer and is expected to make major contributions to the short- and long-term profitability, growth and financial strength of the Company; 

WHEREAS, as the Company’s President and Chief Executive Officer, the Executive will receive: (i) an Annual Base Salary as defined
below; (ii) a Target Bonus as defined below; (iii) an initial grant of equity valued at $12,000,000 at the time of the grant, comprised of $3,600,000 in Restricted Stock Units (“RSUs”) and $8,400,000 in Performance-based
Restricted Stock Units (“PRUs”). Such grants will be made on the date hereof, with the numbers to be granted calculated based on the 20-day trailing average of the value of Symantec’s stock as of the close of business on
September 23, 2014. Executive’s RSUs will have a 3-year vesting schedule, with 30% of the shares vesting in each of the first two years and the remaining 40% vesting in the final year (it being understood that the first vesting date shall
occur on September 1, 2015). Executive’s PRUs shall have the standard 3-year vesting schedule set forth in the Company’s standard form of PRU Agreement; 

WHEREAS, the Company has determined that appropriate arrangements should be taken to encourage the continued attention and dedication of the
Executive to his assigned duties without distraction; 
 WHEREAS, this Agreement supersedes any previous agreement with Executive related to
his position as Interim President and Chief Executive Officer of the Company; 
 WHEREAS, notwithstanding the equity grants made to the
Executive as of the date hereof, the Executive and the Company contemplate that the Executive shall be eligible to receive additional equity compensation in fiscal year 2016 in connection with the Company’s annual focal review process,
commensurate with the Executive’s duties and responsibilities as President and Chief Executive Officer during fiscal year 2016; and 

WHEREAS, in consideration of the Executive’s employment with the Company as of the Hire Date, the Company desires to provide the
Executive with certain compensation and benefits as set forth in this Agreement in order to ameliorate the financial and career impact on the Executive in the event the Executive’s employment with the Company is terminated for a reason related
to, or unrelated to, a Change in Control (as defined below) of the Company. 

  
 1 

 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
hereinafter set forth and intending to be legally bound hereby, the Company and the Executive agree as follows: 
 1. Certain Defined
Terms. In addition to terms defined elsewhere herein, the following terms have the following meanings when used in this Agreement with initial capital letters: 

(a) “Annual Base Salary” means the Executive’s annual base salary rate, exclusive of bonuses, commissions and other incentive
pay, as in effect immediately preceding Executive’s Termination Date. As of the Effective Date, Executive’s Annual Base Salary is $1,000,000. 

(b) “Board” means the Board of Directors of the Company. 

(c) “Cause” means: 

(i) an intentional tort (excluding any tort relating to a motor vehicle) which causes substantial loss, damage or injury to the
property or reputation of the Company or its subsidiaries; 
 (ii) any serious crime or intentional, material act of fraud or
dishonesty against the Company or its subsidiaries; 
 (iii) the commission of a felony that results in other than immaterial
harm to the Company’s business or to the reputation of the Company or Executive; 
 (iv) habitual neglect of
Executive’s reasonable duties (for a reason other than illness or incapacity) which is not cured within ten (10) days after written notice thereof by the Board to the Executive; 

(v) the disregard of written, material policies of the Company or its subsidiaries which causes other than immaterial loss,
damage or injury to the property or reputation of the Company or its subsidiaries which is not cured within ten (10) days after written notice thereof by the Board to the Executive; or 

(vi) any material breach of the Executive’s ongoing obligation not to disclose confidential information and not to assign
intellectual property developed during employment which, if capable of being cured, is not cured within ten (10) days after written notice thereof by the Board to the Executive. 

(d) “Change in Control” means: 

(i) any person or entity becoming the beneficial owner, directly or indirectly, of securities of the Company representing forty
(40%) percent of the total voting power of all its then outstanding voting securities; 
 (ii) a merger or consolidation
of the Company in which its voting securities immediately prior to the merger or consolidation do not represent, or are not converted into securities that represent, a majority of the voting power of all voting securities of the surviving entity
immediately after the merger or consolidation; 

  
 2 

 (iii) a sale of substantially all of the assets of the Company or a liquidation
or dissolution of the Company; or 
 (iv) individuals who, as of the date of the signing of this Agreement, constitute the
Board of Directors (the “Incumbent Board”) cease for any reason to constitute at least a majority of such Board; provided that any individual who becomes a director of the Company subsequent to the date of the signing of this Agreement,
whose election, or nomination for election by the Company stockholders, was approved by the vote of at least a majority of the directors then in office shall be deemed a member of the Incumbent Board. 

(e) “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended. 

(f) “Disability” means: (i) the Executive has been incapacitated by bodily injury, illness or disease so as to be prevented
thereby from engaging in the performance of the Executive’s duties (provided, however, that the Company acknowledges its obligations to provide reasonable accommodation to the extent required by applicable law); (ii) such total incapacity
shall have continued for a period of six (6) consecutive months; and (iii) such incapacity will, in the opinion of a qualified physician, be permanent and continuous during the remainder of the Executive’s life. 

(g) “Good Reason Termination” means: 

(i) a material diminution in the Executive’s base compensation below the amount as of the date of this Agreement or as
increased during the course of his employment with the Company, excluding any reduction generally applicable to all senior executives provided, however, that such exclusion shall not apply if the material diminution in the Executive’s base
compensation occurs within (A) 60 days prior to the consummation of a Change in Control where such Change in Control was under consideration at the time of Executive’s Termination Date or (B) twelve (12) months after the date
upon which such a Change in Control occurs; 
 (ii) a material diminution in the Executive’s authority, duties or
responsibilities; 
 (iii) a requirement that that the Executive report to a corporate officer or employee of the Company
instead of reporting directly to the Board (or if the Company has a parent corporation, a requirement that the Executive report to any individual or entity other than the board of the ultimate parent corporation of the Company); 

(iv) a material change in the geographic location in which the Executive must perform services; or 

(v) any action or inaction that constitutes a material breach by the Company of this Agreement; 

  
 3 

 provided, however, that for the Executive to be able to terminate his employment
with the Company on account of Good Reason he must provide notice of the occurrence of the event constituting Good Reason and his desire to terminate his employment with the Company because of such Good Reason, within ninety (90) days following
the initial existence of the condition constituting Good Reason. The Company must have a period of thirty (30) days following receipt of such notice to cure the condition. If the Company does not cure the event constituting Good Reason within
such thirty (30) day period, the Executive’s Termination Date shall be the day immediately following the end of such thirty (30) day period, unless the Company provides for an earlier Termination Date. 

(h) “Target Bonus” means the target payout (i.e., at 100% achievement of each of the applicable metric(s) in effect from time to
time) under the Company’s Executive Annual Incentive Plan in effect for the Executive as of the Termination Date. As of the Effective Date, Executive’s target bonus percentage under the Executive Annual Incentive Plan is 150% of Annual
Base Salary (it being understood that for fiscal year 2015, the Target Bonus shall be prorated for the time during such fiscal year that the Executive serves as the Company’s President and Chief Executive Officer on a permanent basis). 

(i) “Termination Date” means the last day of Executive’s employment with the Company. 

(j) “Termination of Employment” means the termination of Executive’s active employment relationship with the Company. 

2. Termination Unrelated to a Change in Control. 

(a) Involuntary Termination Unrelated to a Change in Control. In the event of: (i) an involuntary termination of Executive’s
employment by the Company for any reason other than Cause, death or Disability, or (ii) Executive’s resignation for Good Reason, and if Section 3 does not apply, Executive shall be entitled to the benefits provided in subsection
(b) of this Section 2. 
 (b) Compensation Upon Termination Unrelated to a Change in Control. Subject to the provisions of
Section 5, in the event a termination described in subsection (a) of this Section 2 occurs, the Company shall provide Executive with the following, provided that Executive executes and does not revoke the Release (as defined in
Section 5): 
 (i) 3.0 times the sum of Executive’s Annual Base Salary and Target Bonus, paid in a single lump sum
cash payment on the sixtieth (60th) day following Executive’s Termination Date. 
 (ii) For a period of up to
eighteen (18) months following Executive’s Termination Date, Executive and where applicable, Executive’s spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans
in accordance with the terms of the applicable plan documents; provided, that in order to receive such continued coverage at such rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will

  
 4 

 
reimburse the Executive, within 60 days following the date such monthly premium payment is due, an amount equal to the monthly COBRA premium payment, less applicable tax withholdings.
Notwithstanding the foregoing, if Executive obtains full-time employment during this eighteen (18 month period that entitles him and his spouse and eligible dependents to comprehensive medical coverage, Executive must notify the Company and no
further reimbursements will be paid by the Company to the Executive pursuant to this subsection. In addition, if Executive does not pay the applicable monthly COBRA premium for a particular month at any time during the eighteen (18) month
period and coverage is lost as a result, no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide the
foregoing COBRA benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a taxable lump-sum payment in an amount
equal to the monthly (or then remaining) COBRA premium that Executive would be required to pay to continue his group health coverage in effect on the Termination Date (which amount shall be based on the premium for the first month of COBRA
coverage).  
 (iii) Except as provided in Section 3(b)(iii) below, any RSUs that are not vested as of
Executive’s Termination Date shall terminate. 
 (iv) With respect to any (“PRUs”) held by the Executive that
have not been released to the Executive pursuant to the terms of the applicable Performance Based Restricted Share Unit Award Agreement (the “PRU Agreement”) as of the Termination Date shall be treated in accordance with the terms of the
applicable PRU Agreement as an involuntary termination other than for cause. 
 (v) Subject to the provisions of
Section 18, Executive shall receive any amounts earned, accrued or owing but not yet paid to Executive as of his Termination Date, payable in a lump sum, and any benefits accrued or earned in accordance with the terms of any applicable benefit
plans and programs of the Company. 
 3. Termination Related to a Change in Control. 

(a) Involuntary Termination Relating to a Change in Control. In the event Executive’s employment is terminated on account of
(i) an involuntary termination by the Company for any reason other than Cause, death or Disability, or (ii) the Executive voluntarily terminates employment with the Company on account of a resignation for Good Reason, in either case that
occurs (x) at the same time as, or within the twelve (12) month period following, the consummation of a Change in Control or (y) within the sixty (60) day period prior to the date of a Change in Control where the Change in
Control was under consideration at the time of Executive’s Termination Date, then Executive shall be entitled to the benefits provided in subsection (b) of this Section 3. 

  
 5 

 (b) Compensation Upon Involuntary Termination Relating to a Change in Control. Subject to
the provisions of Section 5, in the event a termination described in subsection (a) of this Section 3 occurs, the Company shall provide that the following be paid to the Executive after his Termination Date, provided that Executive
executes and does not revoke the Release: 
 (i) 2.0 times the sum of Annual Base Salary and Target Bonus, paid in a single
lump sum cash payment on the sixtieth (60th) day following Executive’s Termination Date. Notwithstanding the foregoing, to the extent Executive is entitled to receive the severance benefit payable pursuant to Section 2(b)(i) as a
result of a qualifying termination prior to a Change in Control and then becomes entitled to receive the severance benefit payable pursuant to this Section 3 as a result of the Change in Control that was considered at the time of
Executive’s Termination Date becoming consummated within sixty (60) days following Executive’s Termination Date, Executive shall not receive the severance benefit payable pursuant to Section 2(b)(i) of this Agreement, but instead
shall receive the severance benefit payable pursuant to this Section 3(b)(i) on the sixtieth (60th) day following Executive’s Termination Date. 

(ii) For a period of up to eighteen (18) months following Executive’s Termination Date, Executive and where
applicable, Executive’s spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans in accordance with the terms of the applicable plan documents; provided, that in order to
receive such continued coverage at such rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will reimburse the Executive, within sixty (60) days following the date such monthly premium payment
is due, an amount equal to the monthly COBRA (or, as applicable, other) premium payment, less applicable tax withholdings. Notwithstanding the foregoing, if Executive obtains full-time employment during this eighteen (18) month period that
entitles him and his spouse and eligible dependents to comprehensive medical coverage, Executive must notify the Company and no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. In addition, if
Executive does not pay the applicable monthly COBRA (or other) premium for a particular month at any time during the eighteen (18) month period and coverage is lost as a result, no further reimbursements will be paid by the Company to the
Executive pursuant to this subsection. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA benefits without potentially violating applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a taxable lump-sum payment in an amount equal to the monthly (or then remaining) COBRA premium that Executive would be required to pay to
continue his group health coverage in effect on the Termination Date (which amount shall be based on the premium for the first month of COBRA coverage). Notwithstanding the foregoing, to the extent Executive is entitled to receive the severance
benefit provided pursuant to Section 2(b)(ii) of the Agreement as a result of a qualifying termination prior to a Change in Control, if Executive becomes entitled to receive the severance benefits payable pursuant to this Section 3 as a
result of the Change in Control that was considered at the time of Executive’s Termination Date becoming consummated within sixty (60) days following Executive’s Termination Date, Executive shall be entitled to receive the severance
benefit provided pursuant to this clause (ii) and not the benefit provided pursuant to Section 2(b)(ii). 

  
 6 

 (iii) With respect to any RSUs held by the Executive that are unvested at the
time of his Termination Date, all such unvested RSUs shall vest and settle not later than sixty (60) days following the Termination Date. 

(iv) With respect to any PRUs held by the Executive that have not been released to the Executive pursuant to the terms of the
applicable PRU Agreement as of the Termination Date shall be treated in accordance with the terms of the applicable PRU Agreement as a “Change of Control of the Company” (as defined therein). 

(v) Subject to the provisions of Section 18, Executive shall receive any amounts earned, accrued or owing but not yet paid
to Executive as of his Termination Date, payable in a lump sum, and any benefits accrued or earned in accordance with the terms of any applicable benefit plans and programs of the Company. 

4. Termination of Employment on Account of Disability, Death, Cause or Voluntarily Without Good Reason. 

(a) Termination on Account of Disability. Notwithstanding anything in this Agreement to the contrary, if Executive’s employment
terminates on account of Disability, Executive shall be entitled to receive disability benefits under any disability program maintained by the Company that covers Executive, and Executive shall not receive benefits pursuant to Sections 2 and 3
hereof, except that, subject to the provisions of Section 5 hereof, the Executive shall be entitled to the following benefits provided that Executive executes and does not revoke the Release: 

(i) For a period of up to eighteen (18) months following Executive’s Termination Date, Executive and where
applicable, Executive’s spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans in accordance with the terms of the applicable plan documents; provided, that in order to
receive such continued coverage at such rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will reimburse the Executive, within 60 days following the date such monthly premium payment is due, an
amount equal to the monthly COBRA premium payment, less applicable tax withholdings. Notwithstanding the foregoing, if Executive obtains full-time employment during this eighteen (18) month period that entitles him and his spouse and eligible
dependents to comprehensive medical coverage, Executive must notify the Company and no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. In addition, if Executive does not pay the applicable
monthly COBRA premium for a particular month at any time during the eighteen (18) month period and coverage is lost as a result, no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. 

(ii) With respect to any RSUs held by the Executive that are unvested at the time of his Termination Date, all such unvested
Restricted Stock Units shall vest and settle not later than sixty (60) days following his Termination Date. 

  
 7 

 (iii) With respect to any PRUs held by the Executive that have not been released
to the Executive pursuant to the terms of the applicable PRU Agreement as of the Termination Date shall be treated in accordance with the terms of the applicable PRU Agreement as a termination of employment by reason of total and permanent
disability. 
 (b) Termination on Account of Death. Notwithstanding anything in this Agreement to the contrary, if Executive’s employment
terminates on account of death, Executive shall be entitled to receive death benefits under any death benefit program maintained by the Company that covers Executive, and Executive not receive benefits pursuant to Sections 2 and 3 hereof, except
that, subject to the provisions of Section 5 hereof, the Executive shall be entitled to the following benefits provided that Executive’s estate executes and does not revoke the Release: 

(i) With respect to any RSUs held by the Executive that are unvested at the time of his death, all such unvested RSUs shall
vest and settle not later than sixty (60) days following his death. 
 (ii) With respect to any PRUs held by the
Executive that have not been released to the Executive pursuant to the terms of the applicable PRU Agreement as of his death shall be treated in accordance with the terms of the applicable PRU Agreement as a termination of employment by reason of
death. 
 (c) Termination on Account of Cause. Notwithstanding anything in this Agreement to the contrary, if Executive’s
employment terminates by the Company on account of Cause, Executive shall not receive benefits pursuant to Sections 2 and 3 hereof. 
 (d)
Termination on Account of Voluntary Resignation Without Good Reason. Notwithstanding anything in this Agreement to the contrary, if Executive’s employment terminates on account of a resignation by Executive for no reason or any reason
other than on account of Good Reason, Executive shall not receive benefits pursuant to Sections 2 and 3 hereof. 
 5. Release.
Notwithstanding the foregoing, no payments or other benefits under this Agreement shall be made unless Executive executes, and does not revoke, the Company’s standard written release, substantially in the form as attached hereto as Annex
A, (the “Release”), of any and all claims against the Company and all related parties with respect to all matters arising out of Executive’s employment by the Company (other than entitlements under the terms of this Agreement or under
any other plans or programs of the Company in which Executive participated and under which Executive has accrued or become entitled to a benefit) or a termination thereof, with such release being effective not later than sixty (60) days
following Executive’s Termination Date. 
 6. No Mitigation Obligation. Executive shall not be required to mitigate the amount
of any payment or benefit provided for in this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any compensation earned by other employment or otherwise. 

  
 8 

 7. Employment Rights. Nothing expressed or implied in this Agreement will create any right
or duty on the part of the Company or the Executive to have the Executive remain in the employment of the Company or any subsidiary prior to or following any Change in Control. 

8. Tax Matters 
 (a)
Withholding of Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company is required to withhold pursuant to any applicable law, regulation or ruling. 

(b) Parachute Excise Tax. In the event that any amounts payable under this Agreement or otherwise to Executive would (i) constitute
“parachute payments” within the meaning of section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), or any comparable successor provisions and (ii) but for this Subsection (b) would be subject to the
excise tax imposed by section 4999 of the Code or any comparable successor provisions (the “Excise Tax”), then such amounts payable to Executive hereunder shall be either: 

(i) Provided to Executive in full; or 

(ii) Provided to Executive to the maximum extent that would result in no portion of such benefits being subject to the Excise Tax; 

whichever of the foregoing amounts, when taking into account applicable federal, state, local and foreign income and employment taxes, the Excise Tax and any
other applicable taxes, results in the receipt by Executive, on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under the Excise Tax. Unless the Company and Executive
otherwise agree in writing, any determination required under this Subsection (b) shall be made in writing in good faith by a nationally recognized accounting firm (the “Accountants”). In the event of a reduction in benefits hereunder,
the reduction of the total payments shall apply as follows, unless otherwise agreed in writing and such agreement is in compliance with section 409A of the Code: (i) any cash severance payments subject to Section 409A of the Code due under
this Agreement shall be reduced, with the last such payment due first forfeited and reduced, and sequentially thereafter working from the next last payment, (ii) any cash severance payments not subject to Section 409A of the Code due under
this Agreement shall be reduced, with the last such payment due first forfeited and reduced, and sequentially thereafter working from the next last payment; (iii) any acceleration of vesting of any equity subject to Section 409A of the
Code shall remain as originally scheduled to vest, with the tranche that would vest last (without any such acceleration) first remaining as originally scheduled to vest; and (iv) any acceleration of vesting of any equity not subject to
Section 409A of the Code shall remain as originally scheduled to vest, with the tranche that would vest last (without any such acceleration) first remaining as originally scheduled to vest. For purposes of making the calculations required by
this Subsection (b), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of the Code and other applicable legal authority.
The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Subsection (b). The Company shall bear all costs that the Accountants may
reasonably incur in connection with any calculations contemplated by this Subsection (b). 

  
 9 

 If, notwithstanding any reduction described in this Subsection (b), the Internal Revenue Service
(“IRS”) determines that Executive is liable for the Excise Tax as a result of the receipt of amounts payable under this Agreement or otherwise as described above, then Executive shall be obligated to pay back to the Company, within thirty
(30) days after a final IRS determination or, in the event that Executive challenges the final IRS determination, a final judicial determination, a portion of such amounts equal to the Repayment Amount. The “Repayment Amount” with
respect to the payment of benefits shall be the smallest such amount, if any, that is required to be paid to the Company so that Executive’s net after-tax proceeds with respect to any payment of benefits (after taking into account the payment
of the Excise Tax and all other applicable taxes imposed on such payment) are maximized. The Repayment Amount with respect to the payment of benefits shall be zero if a Repayment Amount of more than zero would not result in Executive’s net
after-tax proceeds with respect to the payment of such benefits being maximized. If the Excise Tax is not eliminated pursuant to this paragraph, Executive shall pay the Excise Tax. 

Notwithstanding any other provision of this Subsection (b), if (i) there is a reduction in the payment of benefits as described in this Subsection (b),
(ii) the IRS later determines that Executive is liable for the Excise Tax, the payment of which would result in the maximization of Executive’s net after-tax proceeds (calculated as if Executive’s benefits had not previously been
reduced), and (iii) Executive pays the Excise Tax, then the Company shall pay to Executive those benefits which were reduced pursuant to this Subsection (b) as soon as administratively possible after Executive pays the Excise Tax, so that
Executive’s net after-tax proceeds with respect to the payment of benefits are maximized. 
 9. Successors and Binding
Agreement. 
 (a) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization
or otherwise) to all or substantially all of the business or assets of the Company, by agreement in form and substance reasonably satisfactory to the Executive, expressly to assume and agree to perform this Agreement in the same manner and to the
same extent the Company would be required to perform if no such succession had taken place. This Agreement will be binding upon and inure to the benefit of the Company and any successor to the Company, including without limitation any persons
acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the “Company” for the
purposes of this Agreement), but will not otherwise be assignable, transferable or delegable by the Company. 
 (b) This Agreement will
inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees and legatees. This Agreement will supersede the provisions of any employment, severance
or other agreement between the Executive and the Company that relate to any matter that is also the subject of this Agreement, and such provisions in such other agreements will be null and void. 

  
 10 

 (c) This Agreement is personal in nature and neither of the parties hereto will, without the
consent of the other, assign, transfer or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 9(a) and 9(b). Without limiting the generality or effect of the foregoing, the Executive’s right
to receive payments hereunder will not be assignable, transferable or delegable, whether by pledge, creation of a security interest, or otherwise, other than by a transfer by the Executive’s will or by the laws of descent and distribution and,
in the event of any attempted assignment or transfer contrary to this Section 9(c), the Company will have no liability to pay any amount so attempted to be assigned, transferred or delegated. 

10. Notices. For all purposes of this Agreement, all communications, including without limitation notices, consents, requests or
approvals, required or permitted to be given hereunder will be in writing and will be deemed to have been duly given when hand delivered or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or five
(5) business days after having been mailed by United States registered or certified mail, return receipt requested, postage prepaid, or three business days after having been sent by a nationally recognized overnight courier service such as
FedEx or UPS, addressed to the Company (to the attention of the Secretary of the Company) at its principal executive office and to the Executive at his principal residence, or to such other address as any party may have furnished to the other in
writing and in accordance herewith, except that notices of changes of address will be effective only upon receipt. 
 11.
Section 409A of the Code. 
 (a) Interpretation. Notwithstanding the other provisions hereof, this Agreement is intended
to comply with the requirements of section 409A of the Code, to the extent applicable, and this Agreement shall be interpreted to avoid any penalty sanctions under section 409A of the Code. Accordingly, all provisions herein, or incorporated by
reference, shall be construed and interpreted to comply with section 409A of the Code and, if necessary, any such provision shall be deemed amended to comply with section 409A of the Code and regulations thereunder. If any payment or benefit cannot
be provided or made at the time specified herein without incurring sanctions under section 409A of the Code, then such benefit or payment shall be provided in full at the earliest time thereafter when such sanctions will not be imposed. Any amount
payable under this Agreement that constitutes deferred compensation subject to section 409A of the Code shall be paid at the time provided under this Agreement or such other time as permitted under section 409A of the Code. No interest will be
payable with respect to any amount paid within a time period permitted by, or delayed because of, section 409A of the Code. All payments to be made upon a termination of employment under this Agreement that are deferred compensation may only be made
upon a “separation from service” under section 409A of the Code. For purposes of section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment. In no event may Executive, directly or indirectly,
designate the calendar year of payment. 
 (b) Payment Delay. To the maximum extent permitted under section 409A of the Code, the
severance benefits payable under this Agreement are intended to comply with the “short-term deferral exception” under Treas. Reg. §1.409A-1(b)(4), and any remaining amount is intended to comply with the “separation pay
exception” under Treas. Reg. §1.409A-1(b)(9)(iii); 

  
 11 

 
provided, however, any amount payable to Executive during the six (6) month period following Executive’s Termination Date that does not qualify within either of the foregoing exceptions
and constitutes deferred compensation subject to the requirements of section 409A of the Code, then such amount shall hereinafter be referred to as the “Excess Amount.” If at the time of Executive’s separation from service, the
Company’s (or any entity required to be aggregated with the Company under section 409A of the Code) stock is publicly-traded on an established securities market or otherwise and Executive is a “specified employee” (as defined in
section 409A of the Code and determined in the sole discretion of the Company (or any successor thereto) in accordance with the Company’s (or any successor thereto) “specified employee” determination policy), then the Company shall
postpone the commencement of the payment of the portion of the Excess Amount that is payable within the six (6) month period following Executive’s Termination Date with the Company (or any successor thereto) for six (6) months
following Executive’s Termination Date with the Company (or any successor thereto). The delayed Excess Amount shall be paid in a lump sum to Executive within ten (10) days following the date that is six (6) months following
Executive’s Termination Date with the Company (or any successor thereto). If Executive dies during such six (6) month period and prior to the payment of the portion of the Excess Amount that is required to be delayed on account of section
409A of the Code, such Excess Amount shall be paid to the personal representative of Executive’s estate within sixty (60) days after Executive’s death. 

(c) Reimbursements. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of
section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount
of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the
taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. Any tax gross up payments to be made hereunder shall be made not later than the
end of Executive’s taxable year next following Executive’s taxable year in which the related taxes are remitted to the taxing authority. 

12. Governing Law. The validity, interpretation, construction and performance of this Agreement will be governed by and construed in
accordance with the substantive laws of the State of California, without giving effect to the principles of conflict of laws of such State. 

13. Validity. If any provision of this Agreement or the application of any provision hereof to any person or circumstances is held
invalid, unenforceable or otherwise illegal, the remainder of this Agreement and the application of such provision to any other person or circumstances will not be affected, and the provision so held to be invalid, unenforceable or otherwise illegal
will be reformed to the extent (and only to the extent) necessary to make it enforceable, valid or legal. 
 14. Miscellaneous. No
provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by the Executive and the Company. No waiver by either party hereto at any time of any breach by the

  
 12 

 
other party hereto or compliance with any condition or provision of this Agreement to be performed by such other party will be deemed a waiver of similar or dissimilar provisions or conditions at
the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, expressed or implied with respect to the subject matter hereof have been made by either party that are not set forth expressly in this Agreement.
References to Sections are to references to Sections of this Agreement. Any reference in this Agreement to a provision of a statute, rule or regulation will also include any successor provision thereto. 

15. Board Membership. At each annual meeting of the Company’s stockholders prior to the Termination Date, the Company will
nominate Executive to serve as a member of the Board. Executive’s service as a member of the Board will be subject to any required stockholder approval. Upon the termination of Executive’s employment for any reason, unless otherwise
requested by the Board, Executive agrees to resign from the Board (and all other positions held at the Company and its affiliates), and Executive, at the Board’s request, will execute any documents necessary to reflect his resignation. 

16. Indemnification and D&O Insurance. Executive will be provided indemnification to the maximum extent permitted by the
Company’s and its subsidiaries’ and affiliates’ Articles of Incorporation or Bylaws, including, if applicable, any directors and officers insurance policies, with such indemnification to be on terms determined by the Board or any of
its committees, but on terms no less favorable than provided to any other Company executive officer or director and subject to the terms of any separate written indemnification agreement. 

17. Employee Benefits. Executive will be eligible to participate in the Company employee benefit plans, policies and arrangements that
are applicable to other executive officers of the Company, as such plans, policies and arrangements may exist from time to time and on terms at least as favorable as provided to any other executive officer of the Company. 

18. No Duplication of Benefits. The benefits provided to Executive in this Agreement shall offset substantially similar benefits
provided to Executive pursuant to another Company policy, plan or agreement (including without limitation the Symantec Corporation Executive Severance Plan and the Symantec Corporation Executive Retention Plan). 

19. Survival. Notwithstanding any provision of this Agreement to the contrary, the parties’ respective rights and obligations
under Sections 2 and 3, will survive any termination or expiration of this Agreement or the termination of the Executive’s employment for any reason whatsoever 

20. Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of
which together will constitute one and the same agreement. 

  
 13 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date first
above written. 
  

	
	SYMANTEC CORPORATION
	
	By:
	 /s/ SCOTT C. TAYLOR

	Name: Scott C. Taylor
	Title: EVP, General Counsel & Secretary
	
	EXECUTIVE
	
	 /s/ MICHAEL A. BROWN

	Michael A. Brown

  
 14 

 Annex A 

RELEASE OF CLAIMS 
 This
Release of Claims (“Agreement”) is made by and between Symantec Corporation (“Symantec”) and Michael Brown. 
 WHEREAS,
you have agreed to enter into a release of claims in favor of Symantec upon certain events specified in the Executive Employment Agreement by and between Symantec and you; 

NOW, THEREFORE, in consideration of the mutual promises made herein, Symantec and you agree as follows: 

1. Termination Date. This means the last day of your employment with Symantec. 

2. Acknowledgement of Payment of Wages. You acknowledge that Symantec has paid you all accrued wages, salary, bonuses, accrued but unused vacation pay and any
similar payment due and owing, with the exception of the payments and benefits owed to you under the Executive Employment Agreement and/or under any equity-based compensation awards. 

3. Confidential Information. You hereby acknowledge that you are bound by all confidentiality agreements that you entered into with Symantec and/or any and
all past and current parent, subsidiary, related, acquired and affiliated companies, predecessors and successors thereto (which agreements are incorporated herein by this reference), that as a result of your employment you have had access to the
Confidential Information (as defined in such agreement(s)), that you will hold all such Confidential Information in strictest confidence and that you may not make any use of such Confidential Information on behalf of any third party. You further
confirm that within five business days following the Termination Date you will deliver to Symantec all documents and data of any nature containing or pertaining to such Confidential Information and that you will not take with you any such documents
or data or any reproduction thereof. 
 4. Release and Waiver of All Claims. You waive any limitation on this release under California Civil Code
Section 1542 which provides that a general release does not extend to claims which a person does not know or suspect to exist in his favor at the time of executing the release which, if known, must have materially affected his/her decision to
grant the release. In consideration of the benefits provided in this Agreement, you release Symantec, and any and all past, current and future parent, subsidiary, related and affiliated companies, predecessors and successors thereto, as well as
their officers, directors, shareholders, agents, employees, affiliates, representatives, attorneys, insurers, successors and assigns, from any and all claims, liability, damages or causes of action whatsoever, whether known or unknown, which exist
or may in the future exist arising from or relating to events, acts or omissions on or before the Effective Date of this Agreement, other than those rights which as a matter of law cannot be waived.  

  
 15 

 You understand and acknowledge that this release includes, but is not limited to any claim for reinstatement,
re-employment, damages, attorney fees, stock options, bonuses or additional compensation in any form, and any claim, including but not limited to those arising under tort, contract and local, state or federal statute, including but not limited to
Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Post Civil War Civil Rights Act (42 U.S.C. 1981-88), the Equal Pay Act, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Vietnam Era
Veterans Readjustment Assistance Act, the Fair Labor Standards Act, the Family Medical Leave Act of 1993, the Uniformed Services Employment and Re-employment Rights Act, the Employee Retirement Income Security Act of 1974, and the civil rights,
employment, and labor laws of any state and any regulation under such authorities relating to your employment or association with Symantec or the termination of that relationship. 

You also acknowledge that you are waiving and releasing any rights you may have under the Age Discrimination in Employment Act (ADEA) and that this waiver and
release is knowing and voluntary. You acknowledge that (1) you have been, and hereby are, advised in writing to consult with an attorney prior to executing this Agreement; (2) as consideration for executing this Agreement, you have
received additional benefits and compensation of value to which you would otherwise not be entitled, and (3) by signing this Agreement, you will not waive rights or claims under the Act which may arise after the execution of this Agreement; and
(4) you have twenty-one (21) calendar days within which to consider this Agreement and in the event you sign the Agreement prior to 21days, you do so voluntarily. Once you have accepted the terms of this Agreement, you will have an
additional seven (7) calendar days in which to revoke such acceptance. To revoke, you must send a written statement of revocation to the Vice President of Human Resources. If you revoke within seven (7) days, you will receive no benefits
under this Agreement. In the event you do not exercise your right to revoke this Agreement, the Agreement shall become effective on the date immediately following the seven-day (7) waiting period described above. 

This release does not waive any rights you may have under any directors and officers insurance or indemnity provision, agreement or policy in effect as of the
Termination Date, nor does it affect vested rights you may have under any equity-based compensation plan, retirement plan, 401(k) plan or other benefits plan. 

5. No Pending or Future Lawsuits. You represent that you have no lawsuits, claims, or actions pending in your name or on behalf of any other person or entity,
against Symantec or any other person or entity referred to herein. You also represent that you do not intend to bring any claims on your own behalf or on behalf of any other person or entity against Symantec or any other person or entity referred to
herein. 
 6. Resignation from Board. You agree that you will offer your resignation from the Board of Directors effective upon your Termination Date. The
Board may accept or reject your offer of resignation within its sole and absolute discretion. 
 7. Non disparagement. You agree that you will not, whether
orally or in writing, make any disparaging statements or comments, either as fact or as opinion, about Symantec or its products and services, business, technologies, market position, agents, representatives, directors, officers, shareholders,
attorneys, employees, vendors, affiliates, successors or assigns, or any person acting by, through, under or in concert with any of them. 

  
 16 

 8. Additional Terms 
  

	A.	Legal and Equitable Remedies. You agree that Symantec shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other
rights or remedies Symantec may have at law or in equity for breach of this Agreement. 

  

	B.	Attorney’s Fees. If any action at law or in equity is brought to enforce the terms of this Agreement, the prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees,
costs and expenses at trial or arbitration and any appeal therefrom, in addition to any other relief to which such prevailing party may be entitled. 

  

	C.	Non-Disclosure. You agree to keep the contents, terms and conditions of this Agreement confidential; provided, however that you may disclose this Agreement with your spouse, attorneys, and accountants, or pursuant to
subpoena or court order. Any breach of this non-disclosure paragraph is a material breach of this Agreement. 

  

	D.	No Admission of Liability. This Agreement is not, and the parties shall not represent or construe this Agreement, as an admission or evidence of any wrongdoing or liability on the part of Symantec, its officers,
shareholders, directors, employees, subsidiaries, affiliates, divisions, successors or assigns. Neither party shall attempt to admit this Agreement into evidence for any purpose in any proceeding except in a proceeding to construe or enforce the
terms of this Agreement. 

  

	E.	Entire Agreement. This Agreement along with the Executive Employment Agreement, the Intellectual Property and Confidentiality Agreement, and your written equity award agreements with Symantec, constitutes the entire
agreement between you and Symantec with respect to your separation from Symantec and supersedes all prior negotiations and agreements, whether written or oral, relating to its subject matter. 

 

	F.	Modification/Successors. This Agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement that specifically refers to this Agreement, and that is duly
executed by you and an authorized representative of Symantec. This Agreement shall be binding upon your heirs, executors, administrators and other legal representatives and may be assigned and enforced by Symantec, its successors and assigns.

  

	G.	Severability. The provisions of this Agreement are severable. If any provision of this Agreement or its application is held invalid, the invalidity shall not affect other obligations, provisions, or applications of this
Agreement that can be given effect without the invalid obligations, provisions, or applications. 

  

	H.	Waiver. The failure of either party to demand strict performance of any provision of this Agreement shall not constitute a waiver of any provision, term, covenant, or condition of this agreement or of the right to
demand strict performance in the future. 

  

	I.	Governing Law and Jurisdiction. This Agreement shall be interpreted and enforced in accordance with the laws of the State of California. The exclusive jurisdiction for any action to interpret or enforce this Agreement
shall be the State of California. 

  

	J.	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and same instrument. 

  
 17 

	K.	Voluntary Execution of Agreement. This Agreement is executed voluntarily and without any duress or undue influence on the part of the Parties hereto, with the full intent of releasing all claims. You acknowledge that:

  

	 	a.	You have read this Agreement; 

  

	 	b.	You understand the terms and consequences of this Agreement and the releases it contains; 

  

	 	c.	You have been advised to consult with an attorney prior to executing this Agreement 

  

	 	d.	You knowingly and voluntarily agree to all the terms in this Agreement and; 

  

	 	e.	You knowingly and voluntarily intend to be bound by this Agreement. 

  

													
	 Sign:
	 	  
	  	 	Dated:	  	  	  
	  		  	
					
	 Symantec Corporation
	  				  		  		  	
						
	 By
	 	  
	  	 	Dated:	  	  	  
	  		  	

  
 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]